Golimumab Therapy in Ulcerative Colitis.
- Author:
Won MOON
1
Author Information
- Publication Type:Review
- Keywords: Ulcerative colitis; Tumor necrosis factor-alpha; Infliximab; Adalimumab; Golimumab
- MeSH: Antibodies, Monoclonal/blood/*therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Clinical Trials as Topic; Colitis, Ulcerative/*drug therapy; Drug Administration Schedule; Humans; Treatment Outcome; Tumor Necrosis Factor-alpha/immunology
- From:The Korean Journal of Gastroenterology 2016;67(2):64-73
- CountryRepublic of Korea
- Language:Korean
- Abstract: Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-alpha) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-alpha agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.
